BC
BCRX
BIOCRYST PHARMACEUTICALS INC
$8.70
+2.35%
$2.2B
No data for this timeframe.
Vol
Market Cap$2.2B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders50 funds
Inst. Value$1.2B
Inst. Activity17 buys / 10 sells
Insider Activity0B / 4S
Insider Net $-$2.6M
SEC Reports9
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0000882796·Prev Close $8.50
Recent Activity
Jun 12, 2026
SEC
BioCryst held its 2026 Annual Meeting on June 11, 2026, where shareholders approved an amendment to the Stock Incentive
8-K — Impact 3/10
Jun 12, 2026
Press
BioCryst presented updated clinical data at EAACI 2026, including 48-week ORLADEYO pediatric results showing sustained H
Impact 4/10
Jun 12, 2026
fda
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
<p align="center"><strong>— Growing body of ORLADEYO</strong><sup>®</sup><strong> clinical data and
May 29, 2026
Insider
Frank Steven was granted 1,262 shares
Director @ $8.91 ($11.2K)
May 29, 2026
Insider
MILANO VINCENT was granted 1,122 shares
Director @ $8.91 ($10.0K)
May 29, 2026
Insider
McKee Amy E was granted 631 shares
Director @ $8.91 ($5.6K)
May 19, 2026
SEC
Two BioCryst insiders sold a total of $697K in open-market sales within a week of Q1 2026 earnings. The CLO exercised 62
CLUSTER — Impact 3/10
May 13, 2026
SEC
Officer Alane P. Barnes filed a Form 144 indicating intent to sell 62,500 shares of BioCryst Pharmaceuticals (BCRX), val
144 — Impact 2/10
Price Targets
$21.30
+144.8% upside
Strong Buy
Current $8.70
Low $13.00
Median $19.00
High $32.00
10 analysts
$13.00
$32.00
Analyst Ratings
5Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 7, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| May 7, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| May 6, 2026 | Needham | MAINTAIN | Buy → Buy |
| Jan 30, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.24 ▲ +83.8% | $0.39 — $0.39 | 545% YoY | 2 |
| Next Q | $0.10 ▼ -21.2% | $0.10 — $0.11 | -34% YoY | 2 |
| Current FY | $0.56 ▲ +18.2% | $0.40 — $0.73 | -11% YoY | 2 |
| Next FY | $0.68 ▼ -15.2% | $0.45 — $1.10 | 20% YoY | 3 |
Latest Reports
NEUTRAL
8-K
3/10
BioCryst held its 2026 Annual Meeting on June 11, 2026, where shareholders approved an amendment to the Stock Incentive
Jun 12, 2026
NEUTRAL
Press
4/10
BioCryst presented updated clinical data at EAACI 2026, including 48-week ORLADEYO pediatric results showing sustained H
Jun 12, 2026
NEUTRAL
CLUSTER
3/10
Two BioCryst insiders sold a total of $697K in open-market sales within a week of Q1 2026 earnings. The CLO exercised 62
May 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $215.6M | — |
| RA CAPITAL MANAGEMENT, L.P. | $150.7M | NEW |
| STATE STREET CORP | $116.2M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $107.0M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $106.0M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 29, 2026 | Frank Steven | A | $11.2K |
| May 29, 2026 | MILANO VINCENT | A | $10.0K |
| May 29, 2026 | McKee Amy | A | $5.6K |
| May 29, 2026 | Stonehouse Jon | A | $5.6K |
| May 29, 2026 | Milne Jill | A | $11.2K |
50 institutional holders with $1.2B total value (129,022,800 shares) as of 2026-Q1. Top holders: BlackRock,, RA, STATE. Net buying activity: 17 institutions added/increased vs 10 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 22,650,988 | $215.6M | 17.6% | — |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 15,827,186 | $150.7M | 12.3% | NEW |
| 3 | STATE STREET CORP | 12,208,360 | $116.2M | 9.5% | — |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 11,244,625 | $107.0M | 8.7% | — |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 11,135,762 | $106.0M | 8.6% | — |
| 6 | JANUS HENDERSON GROUP PLC | 8,908,506 | $84.9M | 6.9% | DOUBLED +7807.2% |
| 7 | TWO SIGMA INVESTMENTS, LP | 6,392,628 | $60.9M | 5.0% | — |
| 8 | BANK OF AMERICA CORP /DE/ | 5,091,765 | $48.5M | 3.9% | DOUBLED +231.6% |
| 9 | Nuveen, LLC | 3,819,263 | $36.4M | 3.0% | — |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2,815,304 | $26.8M | 2.2% | — |
| 11 | DIMENSIONAL FUND ADVISORS LP | 2,690,651 | $25.6M | 2.1% | DOUBLED +119.0% |
| 12 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,350,405 | $22.4M | 1.8% | — |
| 13 | GOLDMAN SACHS GROUP INC | 2,347,443 | $22.3M | 1.8% | — |
| 14 | MORGAN STANLEY | 2,022,988 | $19.3M | 1.6% | TRIM -66.5% |
| 15 | STIFEL FINANCIAL CORP | 1,825,184 | $17.4M | 1.4% | — |
| 16 | VANGUARD FIDUCIARY TRUST CO | 1,664,297 | $15.8M | 1.3% | — |
| 17 | Legal & General Group Plc | 1,411,199 | $13.4M | 1.1% | DOUBLED +568.8% |
| 18 | Invesco Ltd. | 1,308,813 | $12.5M | 1.0% | ADD +40.8% |
| 19 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 1,227,040 | $11.7M | 1.0% | NEW |
| 20 | JUPITER ASSET MANAGEMENT LTD | 1,196,371 | $11.4M | 0.9% | TRIM -41.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,535,557 | 5,091,765 | +231.6% | $48.5M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 1,228,852 | 2,690,651 | +119.0% | $25.6M | 2026-Q1 |
| Legal & General Group Plc | DOUBLED | 210,999 | 1,411,199 | +568.8% | $13.4M | 2026-Q1 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | NEW | — | 1,227,040 | — | $11.7M | 2026-Q1 |
| DEUTSCHE BANK AG\ | ADD | 491,086 | 821,367 | +67.3% | $7.8M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | DOUBLED | 374,961 | 800,900 | +113.6% | $7.6M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 2,128,821 | 776,990 | -63.5% | $7.4M | 2026-Q1 |
| Hudson Bay Capital Management LP | TRIM | 1,017,374 | 490,369 | -51.8% | $4.7M | 2026-Q1 |
| Pictet Asset Management Holding SA | TRIM | 740,510 | 471,573 | -36.3% | $4.5M | 2026-Q1 |
| Gotham Asset Management, LLC | ADD | 216,946 | 312,961 | +44.3% | $3.0M | 2026-Q1 |
| MACKENZIE FINANCIAL CORP | ADD | 150,728 | 243,416 | +61.5% | $2.3M | 2026-Q1 |
| Assenagon Asset Management S.A. | TRIM | 359,580 | 232,947 | -35.2% | $2.2M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 103,157 | 150,264 | +45.7% | $1.4M | 2026-Q1 |
| GROUP ONE TRADING LLC | DOUBLED | 60,524 | 136,282 | +125.2% | $1.3M | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | TRIM | 327,941 | 118,005 | -64.0% | $1.1M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | DOUBLED | 12,790 | 53,776 | +320.5% | $511.9K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | NEAR_EXIT | 355,055 | 48,900 | -86.2% | $465.5K | 2026-Q1 |
| LAZARD ASSET MANAGEMENT LLC | TRIM | 69,598 | 36,360 | -47.8% | $346.1K | 2026-Q1 |
| Rockefeller Capital Management L.P. | ADD | 26,797 | 34,882 | +30.2% | $332.1K | 2026-Q1 |
| HSBC HOLDINGS PLC | ADD | 24,133 | 31,499 | +30.5% | $302.7K | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | NEAR_EXIT | 325,051 | 26,356 | -91.9% | $250.9K | 2026-Q1 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 10,231 | 13,082 | +27.9% | $124.5K | 2026-Q1 |
| CWM, LLC | TRIM | 8,361 | 5,931 | -29.1% | $56.5K | 2026-Q1 |
| NATIONAL BANK OF CANADA /FI/ | DOUBLED | 500 | 5,700 | +1040.0% | $54.3K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 2,168 | 2,883 | +33.0% | $27.4K | 2026-Q1 |
8 unique insiders with 20 transactions. Net insider value: -$2.6M ($0.00 bought, $2.6M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 29, 2026 | Frank Steven | Director | AWARD | 1,262 | $8.91 | $11.2K |
| May 29, 2026 | MILANO VINCENT | Director | AWARD | 1,122 | $8.91 | $10.0K |
| May 29, 2026 | McKee Amy E | Director | AWARD | 631 | $8.91 | $5.6K |
| May 29, 2026 | Stonehouse Jon P | Director | AWARD | 631 | $8.91 | $5.6K |
| May 29, 2026 | Milne Jill C. | Director | AWARD | 1,262 | $8.91 | $11.2K |
| May 18, 2026 | McKee Amy E | Director | SELL | 11,180 | $8.97 | $100.3K |
| May 13, 2026 | Barnes Alane P | Chief Legal Officer | EXERCISE | 62,500 | $5.04 | $315.0K |
| May 13, 2026 | Barnes Alane P | Chief Legal Officer | SELL | 62,500 | $9.54 | $596.3K |
| Apr 6, 2026 | Menon Sandeep | Chief R&D Officer | AWARD | 441,350 | — | — |
| Apr 6, 2026 | Menon Sandeep | Chief R&D Officer | AWARD | 205,150 | — | — |
| Mar 20, 2026 | HEGGIE THERESA | Director | EXERCISE | 49,933 | $6.30 | $314.6K |
| Mar 20, 2026 | HEGGIE THERESA | Director | SELL | 49,933 | $10.11 | $504.8K |
| Mar 16, 2026 | Barnes Alane P | Chief Legal Officer | EXERCISE | 150,000 | $5.51 | $826.5K |
| Mar 16, 2026 | Barnes Alane P | Chief Legal Officer | SELL | 150,000 | $9.15 | $1.4M |
| Mar 2, 2026 | Stonehouse Jon P | Director | EXERCISE | 305,995 | $3.22 | $985.3K |
| Feb 27, 2026 | Milne Jill C. | Director | AWARD | 528 | $8.75 | $4.6K |
| Feb 27, 2026 | Frank Steven | Director | AWARD | 1,285 | $8.75 | $11.2K |
| Feb 27, 2026 | MILANO VINCENT | Director | AWARD | 848 | $8.75 | $7.4K |
| Feb 27, 2026 | Stonehouse Jon P | Director | AWARD | 421 | $8.75 | $3.7K |
| Feb 27, 2026 | McKee Amy E | Director | AWARD | 642 | $8.75 | $5.6K |
9 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 7 neutral. Avg impact: 4.2/10.
NEUTRAL
8-K
3/10
BioCryst held its 2026 Annual Meeting on June 11, 2026, where shareholders approved an amendment to
Jun 12, 2026
NEUTRAL
CLUSTER
3/10
Two BioCryst insiders sold a total of $697K in open-market sales within a week of Q1 2026 earnings.
May 19, 2026
NEUTRAL
144
2/10
Officer Alane P. Barnes filed a Form 144 indicating intent to sell 62,500 shares of BioCryst Pharmac
May 13, 2026
NEUTRAL
8-K
5/10
BioCryst reported Q1 2026 ORLADEYO revenue of $148.3M (+11% y-o-y; +21% on a comparable ex-Europe ba
May 6, 2026
BULLISH
8-K
7/10
BioCryst entered a European licensing agreement for navenibart (HAE) with Neopharmed Gentili, receiv
May 4, 2026
NEUTRAL
DEFA14A
3/10
BioCryst Pharmaceuticals is holding its 2026 annual meeting to vote on several proposals, including
Apr 23, 2026
NEUTRAL
PRESS-RELEASE
3/10
BioCryst Pharmaceuticals announced it will report Q1 2026 financial results on May 6, 2026, but prov
Apr 15, 2026
NEUTRAL
CLUSTER
4/10
Director Theresa Heggie sold 49,933 shares of BioCryst Pharmaceuticals for $504,823 in an open-marke
Mar 24, 2026
BULLISH
8-K
8/10
BioCryst reported a transformative 2025 with $601.8 million in ORLADEYO net revenue (up 38% YoY), ac
Feb 26, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 5 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$21.30 mean target
+144.8% upside
Strong Buy (3.00)
$13.00 Low
$32.00 High
| Metric | Value |
|---|---|
| Current Price | $8.70 |
| Target Low | $13.00 |
| Target Mean | $21.30 |
| Target Median | $19.00 |
| Target High | $32.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.24 | $0.39 | $0.39 | 544.7% | +83.8% | — | $0.2B | 13.7% | 2 |
| Next Q 2026-09-30 |
$0.10 | $0.10 | $0.11 | -34.4% | -21.2% | 0↑ 1↓ | $0.2B | 4.2% | 2 |
| Current FY 2026-12-31 |
$0.56 | $0.40 | $0.73 | -11.0% | +18.2% | 2↑ 0↓ | $0.7B | -23.4% | 2 |
| Next FY 2027-12-31 |
$0.68 | $0.45 | $1.10 | 20.3% | -15.2% | 1↑ 2↓ | $0.7B | 8.5% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.245 | |
| 7d ago | $0.133 | +0.112 |
| 30d ago | $0.133 | +0.112 |
| 60d ago | $0.133 | +0.112 |
| 90d ago | $0.150 | +0.095 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 7, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| May 7, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| May 6, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jan 30, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 5 | 8 | 2 | 0 | 0 | 87% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 12, 2026
fda
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
<p align="center"><strong>— Growing body of ORLADEYO</strong><sup>®</sup><strong> clinical data and real-world evidence demonstrates consistent reduct
Jun 12, 2026
Clinical Trial
A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD
Phase Phase 2 — COMPLETED
Jun 9, 2026
other
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=vS8nc4QnNY7Dl
May 19, 2026
short_volume
Short Volume: BCRX — 55.4% short (0.7M / 1.3M)
Short: 710,712 | Exempt: 2,040 | TRF Vol: 1,281,838 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: BCRX — 55.4% short (0.9M / 1.7M)
Short: 921,290 | Exempt: 3,354 | TRF Vol: 1,662,822 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: BCRX — 65.8% short (1.2M / 1.9M)
Short: 1,240,838 | Exempt: 510 | TRF Vol: 1,884,419 | Short Ratio: 65.8% | Off-exchange volume (dark pool + OTC)
May 13, 2026
other
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
<p align="justify">RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=zAcHAlogcHCfWl
May 6, 2026
earnings
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><strong><em>— Q1 2026 ORLADEYO</em></strong><sup>®</sup><strong><em> net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on compar
May 6, 2026
earnings_calendar
BCRX Q1 2026 Earnings Before Market Open — 2026-05-06
May 4, 2026
other
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
<p align="center"><strong><em>— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary ang
May 1, 2026
short_volume
Short Volume: BCRX — 56.2% short (0.5M / 0.9M)
Short: 503,695 | Exempt: 0 | TRF Vol: 896,359 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
other
BioCryst to Present at Upcoming Investor Conferences
<p align="justify">RESEARCH TRIANGLE PARK, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=IAf7E828YKqb
Apr 24, 2026
short_volume
Short Volume: BCRX — 55.4% short (0.4M / 0.8M)
Short: 428,402 | Exempt: 2,816 | TRF Vol: 773,368 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
earnings
BioCryst to Report First Quarter 2026 Financial Results on May 6
<p align="justify">RESEARCH TRIANGLE PARK, N.C. , April 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=C2dZbtCM4DV
Apr 15, 2026
short_volume
Short Volume: BCRX — 58.3% short (1.4M / 2.5M)
Short: 1,445,044 | Exempt: 1,000 | TRF Vol: 2,479,109 | Short Ratio: 58.3% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
short_interest
FTD: BCRX — 93,634 shares ($0.9M) failed to deliver
Settlement: 20260414, Price: $9.41, FTD Value: $881,095.94, BIOCRYST PHARMACEUTICALS INC